Novartis

Novartis

Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

Novartis products include oncology medicines, generic and biosimilar medicines and eye care devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines.

Divisions

Novartis Oncology

Novartis Oncology is focused on the development and manufacturing of medicines directed towards improving and extending people's lives.

Sandoz

Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals.

Alcon

Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery.

Novartis Gene Therapies

Previously known as AveXis, Novartis Gene Therapies works to develop and commercialize gene therapies. They have a specific focus on neurological genetic diseases. Their initial gene therapy is for spinal muscular atrophy and has been approved in the United States, Japan, the European Union, and Brazil.

Novartis Institutes for BioMedical Research (NIBR)

Part of their research and development program, the Novartis Institutes for BioMedical Research (NIBR) is working on developing informatics tools for drug discovery with a focus on open-sourced software.

Habitat

Habitat is a software developed to be a self-contained object storage management system. Based on Amazon Web Services, Novartis says Habitat is capable of virtually unlimited storage and can be used as a local repository for a single application or shared and used with many clients.

Yet Another Data Abstraction (YADA)

Novartis says Yet Another Data Abstraction (YADA) is a data aggregation tool capable of accessing data sets at any data source in any format and from any environment with a single URL and a single configuration. YADA is intended to be a lightweight framework for data retrieval, searching, storage, and manipulation.

OntoBrowser

OntoBrowser is a web-based application for managing ontologies. Developed by Novartis, they say the tool is intended to provide an online collaborative solution for curators to map code list terms to preferred ontology terms. OntoBrowser also offers visualization of ontologies in hierarchical or graph format, advanced search capabilities, and web service access to data.

Railroadtracks

Railroadtracks is a Python package Novartis says is intended to handle connected computation steps for DNA and RNA sequencing.

Yet Another Pipeline (YAP)

Yet Another Pipeline (YAP) is an extensible parallel framework developed by Novartis and written in Python using OpenMPI libraries. The software is intended to help researchers build high throughput data pipelines without knowledge of parallel programming.

RDKit

Developed by Novartis, the RDKit is a collection of cheminformatics and machine-learning softwre written in C++ and Python. The distribution includes a PostgreSQL-based cartridge allowing molecules to be stored in a relational database and allowing users to retrieve information via substructure and similarity searches.

GridVar

GridVar is a JQuery plugin that visualized multi-dimensional datasets as layers organized in a row-column format. Novartis says the software is intended to allow users to visualize data as a background color and enables characteristics of a dataset to be layered on top of each other.

Nerve Live

Developed by Novartis to use big data and data analytics, Nerve Live is an advanced analytics platform is intended to be used as part of a drug discovery program. Novartis sees the platform as enabling machine learning and cognitive computing systems to extract information which traditional data analysts and users might miss.

The Nerve Live was developed by first building a data lake. This was followed by developing an analytics engine to process the data and derive assets from it. And the final stage of development of this program involved designing user modules that would make predictive analytic insights and offer these insights to add value in business decisions.

Novartis hopes to develop Nerve Live to offer features to help manage resources, including using predictive models to plan medical supplies for medical centers.

data42 Program

The data42 program is a digital research and development platform Novartis believes will help in drug discovery and drug testing while costing less. The program would include large pools of patient and pharmaceutical data and an artificial intelligence to assist researchers in their development. As of March 2020, the program was still in the initial phases of development.

Research

Gleevec

Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.

Kisqali

Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.

Timeline

May 15, 2020

Novartis CEO says any new coronavirus vaccine will take two years.

April 20, 2020

Novartis acquires Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye".

November 24, 2019

Novartis entered into an agreement and plan of merger with The Medicines Company to acquire the US-based biopharmaceutical company for USD 85.00 per share in cash, valuing the company at approximately USD 9.7 billion on a fully diluted equity basis.

October 1, 2019

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence.

May 9, 2019

Novartis acquires Xiidra, expanding front-of-eye portfolio.

April 1, 2019

Novartis agrees to pay $310 million, with the possibility for more later, for some assets of Boston-based IFM Therapeutics.

April 9, 2018

Novartis acquires AveXis, a gene therapy company, for $8.7 billion.

December 20, 2016

Swiss drug maker Novartis AG reached a definitive agreement to acquire Fort Worth, Texas-based Encore Vision, which is focused on developing a novel treatment in presbyopia, or far-sightedness.

2010

Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Novartis Grant (money), February 2018
6,500,000
February 14, 2018
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Barry X Lynn

Investor

Chris Ilsley

President, Chief Executive Officer

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Ken Londoner

Advisor

Mike Ryan

Investor

prakash thombre

Investor

Stacia Danielle Sullivan

Founder

Steven Zeppenfeld

Investor

V and K Law

Attorney

Further reading

Title
Author
Link
Type
Date

Drug development gets big data analytics boost

Goran Mijuk

Web

July 2, 2018

The data42 program shows Novartis' intent to go big on data and digital

Goran Mijuk

Web

March 11, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Megan Twohey and Nicholas Kulish | NYT
November 23, 2020
@bsindia
If the initiative, aided by Mr. Gatess fortune and focus, manages to help protect the worlds poor from a virus it will affirm the strategies he has promoted in his philanthropic work
Mark Terry
November 20, 2020
BioSpace
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to COVID-19.
Nick Paul
November 20, 2020
FierceBiotech
Novartis has secured a global license to Mesoblast's cell therapy remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and the support of a partner that could help address critical quality attribute concerns raised by the FDA.
DNA Web Team
November 19, 2020
DNA India
Why Covid-19 vaccines could further harm critically endangered deep-sea shark species? - At least five of the 202 Covid-19 vaccine being made by various pharmaceutical companies around the world are relying on squalene, sourced from wild-caught sharks.
Novartis Pharmaceuticals Corporation
November 19, 2020
www.prnewswire.com:443
/PRNewswire/ -- Novartis announced today that new research data from a broad range of hematology medicines and investigational therapies will be presented at...
ConcertAI
November 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- ConcertAI announced a multi-year collaboration with Novartis to advance research-grade real-world data (RWD) and advanced analytic technologies...
Cleveland Clinic
November 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Findings from a new Cleveland Clinic study do not support the use of a high dose omega-3 fatty acid formulation to reduce major adverse...
November 13, 2020
BioSpace
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender - read this article along with other careers information, tips and advice on BioSpace
Novartis Pharmaceuticals Corporation
November 13, 2020
www.prnewswire.com:443
/PRNewswire/ -- Novartis today announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 trials, evaluating the impact of age and...
West Pharmaceutical Services, Inc.
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced it has...
Alex Keown
November 6, 2020
BioSpace
This morning, the Swiss pharma giant announced Ilaris plus standard of care did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus the standard of care.
November 5, 2020
BioSpace
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study - read this article along with other careers information, tips and advice on BioSpace
Robert King
August 25, 2020
FierceHealthcare
Drug manufacturers are getting more aggressive in their moves to restrict access to 340B drugs as legal experts say the Trump administration is not stepping in.
Heather Landi
August 12, 2020
FierceHealthcare
There is a potential deal on the table for Proteus Digital Health to exit bankruptcy in a $15 million sale to Otsuka Pharmaceutical. In an 11th-hour play, a group of investors including drug giant Novartis are trying to push off that sale.
Amirah Al Idrus
July 17, 2020
FierceBiotech
Eli Lilly's anti-IL-23 antibody beat placebo at clearing psoriasis symptoms in a phase 3 study, teeing up regulatory filings across the globe. But that's not all--the drug also outshone Novartis' blockbuster Cosentyx in the same study.
Conor Hale
July 7, 2020
FierceBiotech
Novartis has teamed up with smart inhaler developer Propeller Health to package and ship its digital medication-tracking platform alongside the Big Pharma's newly approved asthma treatment in Europe.
Steven Levy
June 30, 2020
Wired
Vas Narasimhan talks about drug prices, vaccine development, the rise and fall of hydroxychloroquine, and how Big Pharma might win back the trust of consumers.
Nick Paul
June 15, 2020
FierceBiotech
UCB has presented detailed phase 3 data on psoriasis prospect bimekizumab, raising expectations that it can deliver a telling blow to Novartis' Cosentyx in an upcoming head-to-head study. Shares in UCB, a company valued above $20 billion, jumped 14% in response to the readout.
Alex Keown
June 11, 2020
BioSpace
In the latest legal action, the attorneys general from 46 states, the District of Columbia and four U.S. territories accused the drug makers of conspiring to rig the price of approximately 80 generic drugs between 2009 and 2016
Alex Keown
June 3, 2020
BioSpace
On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.
SHOW MORE

References

Page 1 of 3
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.